"Recycled" headlines are being weaponized by short sellers to drive the price down, despite the facts being largely known.
$Hims & Hers Health Inc.(HIMS)$
Status: Bearish (Artificial Pressure)
1. The Short Seller's Playbook
It’s clear that someone is trying to push the share price lower by circulating "stale" news. The headlines about Amazon’s push into GLP-1 and Eli Lilly’s Foundayo aren’t fundamentally new, but they are being timed to hit the tape while the stock is vulnerable.
The Goal: Trigger stop-losses and panic selling among retail investors who may have missed the original news cycle in 2025.
The Weapon: Amazon's $149/month price point for branded oral pills. While Hims already knew this was coming, seeing it operationalized is a "scare tactic" used to justify a short position.
10 April old news.
2. Current Short Interest Dynamics
Data as of mid-April shows that HIMS has become one of the most heavily shorted mid-cap stocks on the market:
Short Interest: Currently sitting at a staggering 32.5% to 34% of the float.
The "Short Volume Ratio": Recent daily trading data shows that over 57% to 64% of the daily volume is short-selling.
Interpretation: This isn't just organic selling; this is a concentrated effort to keep the stock under $30 ahead of the May earnings report.
@TigerPM @Daily_Discussion @TigerObserver @MillionaireTiger @TigerStars
Comments
Meanwhile, I bought the dip.